Lin Yansong
Department of Nuclear Medicine, Peking Union Medical College Hospital , Beijing 100730 , China .
J Biomed Res. 2015 Sep;29(5):345-55. doi: 10.7555/JBR.29.20140069. Epub 2015 Jan 12.
With increasing evidence, internal radiation therapy, also known as brachytherapy, has become a neglected aspect of nuclear medicine in the molecular era. In this paper, recent developments regarding internal radiation therapy, including developments in radioiodine-131 ((131)I) and thyroid, radioimmunotherapy (RIT) for non-Hodgkin lymphoma (NHL), and radiopharmaceuticals for bone metastases. Relevant differences and status of their applications in China were mentioned as well. These molecular mediated internal radiation therapies are gaining increasing importance by providing palliative and curative treatments for an increasing number of diseases and becoming one of the important parts of molecular nuclear medicine.
随着证据的不断增加，内照射治疗，也称为近距离放射治疗，在分子时代已成为核医学中一个被忽视的领域。本文介绍了内照射治疗的最新进展，包括131碘（131I）与甲状腺、非霍奇金淋巴瘤（NHL）的放射免疫治疗（RIT）以及骨转移瘤的放射性药物。文中还提及了它们在中国应用的相关差异和现状。这些分子介导的内照射治疗通过为越来越多的疾病提供姑息性和治愈性治疗，正变得越来越重要，并成为分子核医学的重要组成部分之一。
